<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492700</url>
  </required_header>
  <id_info>
    <org_study_id>LIDO-Trials-01</org_study_id>
    <nct_id>NCT00492700</nct_id>
  </id_info>
  <brief_title>A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis</brief_title>
  <acronym>FLIRT</acronym>
  <official_title>A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour la Recherche sur les Maladies Hépatiques Virales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association pour la Recherche sur les Maladies Hépatiques Virales</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to find out whether treatment with rosiglitazone improves the state of
      the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase one : A double blind randomized placebo controlled trial of rosiglitazone

        -  64 pts with biopsy proven NASH will be randomized to receive either rosiglitazone 8
           mg/day or placebo for one year.

        -  after one year of treatment patients will undergo a liver biopsy then a 4 month follow
           off treatment

      Primary endpoint: improvement of at least 30% of the histological score of steatosis
      Secondary endpoints: improvement in ALT values, in necrosis and inflammation and fibrosis

      Phase II extension open label trial

      All participants to the phase one regardless of the drug received in the first year will be
      treated with rosiglitazone for 2 additional years. A liver biopsy will be performed at the
      end of these two additional years in order to find out whether prolonged rosiglitazone
      therapy further results in improvement of liver injury in NASH patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in steatosis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis</measure>
  </secondary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven NASH with steatosis &gt;= 20%

          -  Increased serum ALT

        Exclusion Criteria:

          -  bland steatosis

          -  daily alcohol &gt; 20/30 g (women/men)

          -  any other cause of liver disease

          -  secondary NASH including drug-induced steatohepatitis

          -  treatment with insulin or glitazones

          -  cardiac insufficiency

          -  Hb &lt; 10 g/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad Ratziu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié Salpêtrière, APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'hépatogastroenérologie, Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>June 26, 2007</last_update_submitted>
  <last_update_submitted_qc>June 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2007</last_update_posted>
  <keyword>steatosis,</keyword>
  <keyword>fibrosis,</keyword>
  <keyword>diabetes,</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

